Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04952597 · ClinicalTrials.gov registry record · Phase 2
Study of Ociperlimab Plus Tislelizumab Plus Chemoradiotherapy in Participants With Untreated Limited-Stage Small Cell Lung Cancer
A Phase 2 study, sponsored by BeiGene.
- Completed
- Registry status
- Phase 2
- Development phase
- 126
- Enrollment target
NCT04952597 is a Phase 2 study that has completed, run by BeiGene. The registered enrollment target is 126 participants.
The verdict
NCT04952597, a Phase 2 study, has completed, sponsored by BeiGene.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 126 participants
- Enrollment target
Study Summary
This phase 2 trial examined whether the preliminary efficacy and safety of ociperlimab, tislelizumab, and cCRT when used in combination is expected to advance treatment options in the serious unmet medical need population of Limited-Stage Small Cell Lung Cancer (LS-SCLC) participants .
Interventions
- DRUG Tislelizumab
- DRUG Ociperlimab
- DRUG Concurrent Chemoradiotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 126 participants |
| Start Date | 2021-07-15 |
| Est. Completion | 2023-07-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04952597
The ClinicalTrials.gov registry entry for NCT04952597 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 126 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BeiGene, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Tislelizumab is the first listed.
NCT04952597 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04952597 about?
NCT04952597 is a clinical study titled "Study of Ociperlimab Plus Tislelizumab Plus Chemoradiotherapy in Participants With Untreated Limited-Stage Small Cell Lung Cancer". This phase 2 trial examined whether the preliminary efficacy and safety of ociperlimab, tislelizumab, and cCRT when used in combination is expected to advance treatment options in the serious unmet medical need population of Limited-Stage Small Cell Lung Cancer (LS-SCLC) participants .
What is the current status of trial NCT04952597?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 126 participants. The study started on 2021-07-15. Estimated completion is 2023-07-26.
What interventions are being tested in trial NCT04952597?
The interventions under investigation include: Tislelizumab (DRUG), Ociperlimab (DRUG), Concurrent Chemoradiotherapy (DRUG).
Who is sponsoring clinical trial NCT04952597?
This trial is sponsored by BeiGene, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.